233 related articles for article (PubMed ID: 25745966)
1. [Successful treatment with azacitidine for myelodysplastic syndrome with large vessel vasculitis].
Mishima M; Makita M; Sando Y; Yamamoto Y; Shiote Y; Hara Y; Yamamoto K; Imajo K
Rinsho Ketsueki; 2015 Jan; 56(1):35-7. PubMed ID: 25745966
[TBL] [Abstract][Full Text] [Related]
2. Moleculary Confirmed, Cytogenetic Remission in a Case with Myelodysplastic Syndrome Treated with Azacitidne.
Panovska-Stavridis I; Ivanovski M; Trajkova S; Pivkova-Veljanovska A; Popova-Labaceska M; Matevska-Geshovska N; Noveski P; Plaseska-Karanfilska D; Cevreska L; Dimovski AJ
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Dec; 38(3):157-162. PubMed ID: 29668469
[TBL] [Abstract][Full Text] [Related]
3. Recurrence of abdominal large-vessel vasculitis and development of severe Sweet syndrome after a single cycle of 5-azacytidine in a patient with myelodysplastic syndrome.
Kawano H; Suzuki T; Ishii S; Wakahashi K; Kawano Y; Sada A; Minagawa K; Ueno D; Yamasaki T; Itoh T; Yokozaki H; Katayama Y
Eur J Haematol; 2014 Apr; 92(4):362-4. PubMed ID: 24341928
[No Abstract] [Full Text] [Related]
4. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.
Götze K; Platzbecker U; Giagounidis A; Haase D; Lübbert M; Aul C; Ganser A; Germing U; Hofmann WK
Ann Hematol; 2010 Sep; 89(9):841-50. PubMed ID: 20567826
[TBL] [Abstract][Full Text] [Related]
5. Large vessel vasculitis with myelodysplastic syndrome.
Katsuyama T; Uchida HA; Toma K; Maeda Y; Hirota D; Umebayashi R; Sada KE; Makino H
Intern Med; 2014; 53(1):63-6. PubMed ID: 24390531
[TBL] [Abstract][Full Text] [Related]
6. Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5-azacytidine and literature review.
Frietsch JJ; Dornaus S; Neumann T; Scholl S; Schmidt V; Kunert C; Sayer HG; Hochhaus A; La Rosée P
Eur J Haematol; 2014 Sep; 93(3):247-59. PubMed ID: 24635656
[TBL] [Abstract][Full Text] [Related]
7. Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome.
Kataoka A; Mizumoto C; Kanda J; Iwasaki M; Sakurada M; Oka T; Fujimoto M; Yamamoto Y; Yamashita K; Nannya Y; Ogawa S; Takaori-Kondo A
Int J Hematol; 2023 Jun; 117(6):919-924. PubMed ID: 36641501
[TBL] [Abstract][Full Text] [Related]
8. [Large vessel vasculitis with myelodysplastic syndrome: A rare association].
Galland J; Kawski H; Guichard JF; Maurier F
Rev Med Interne; 2017 Jul; 38(7):474-477. PubMed ID: 28094068
[TBL] [Abstract][Full Text] [Related]
9. Remission of relapsing polychondritis after successful treatment of myelodysplastic syndrome with azacitidine: a case and review of the literature.
Erden A; Bilgin E; Kılıç L; Sarı A; Armağan B; Büyükaşık Y; Kalyoncu U
Drug Metab Pers Ther; 2018 Jun; 33(2):105-108. PubMed ID: 29715182
[TBL] [Abstract][Full Text] [Related]
10. Late-onset Erythropoietic Protoporphyria Associated with Myelodysplastic Syndrome Treated with Azacitidine.
Yoshioka A; Fujiwara S; Kawano H; Nakano H; Taketani S; Matsui T; Katayama Y; Nishigori C
Acta Derm Venereol; 2018 Feb; 98(2):275-277. PubMed ID: 29057424
[No Abstract] [Full Text] [Related]
11. Successful treatment by azacitidine therapy of intestinal Behçet's disease associated with myelodysplastic syndrome.
Tanaka H; Shimizu N; Tougasaki E; Kawajiri C; Hashimoto S; Takeda Y; Sakai S; Takeuchi M; Ohwada C; Sakaida E; Takagi T; Nakaseko C
Int J Hematol; 2013 Apr; 97(4):520-4. PubMed ID: 23519573
[TBL] [Abstract][Full Text] [Related]
12. [Myelodysplastic syndrome with neutrophilic dermatosis successfully treated with azacitidine].
Kudo D; Shimizu M; Kuroda A; Suyama T; Shinagawa A; Ito S
Rinsho Ketsueki; 2017; 58(6):607-612. PubMed ID: 28679990
[TBL] [Abstract][Full Text] [Related]
13. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
[TBL] [Abstract][Full Text] [Related]
14. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
15. [Unidentified Inflammatory Disease Induced by Azacitidine Therapy for Myelodysplastic Syndrome].
Inagaki S; Tamai Y; Yoshizawa M; Sato S; Kanbe E; Tanaka E
Gan To Kagaku Ryoho; 2015 Nov; 42(11):1443-6. PubMed ID: 26602409
[TBL] [Abstract][Full Text] [Related]
16. [Successful treatment with azacitidine for a patient with relapsed myelodysplastic syndrome after cord blood transplantation].
Ueda S; Miyakoshi S; Chizuka A; Kojima R; Ogasawara T; Miyamoto K
Rinsho Ketsueki; 2013 Dec; 54(12):2177-81. PubMed ID: 24452149
[TBL] [Abstract][Full Text] [Related]
17. Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine.
Kim DY; Lee JH; Lee JH; Lee KH; Kim YK; Ahn JS; Kim HJ; Kim I; Yoon SS; Park S; Bae SH; Bang SM; Lee HG; Shin HJ; Lee JH; Min YH; Won JH; Mun YC; Oh D;
Ann Hematol; 2010 Jan; 89(1):15-23. PubMed ID: 19543727
[TBL] [Abstract][Full Text] [Related]
18. A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.
Thepot S; Boehrer S; Seegers V; Prebet T; Beyne-Rauzy O; Wattel E; Delaunay J; Raffoux E; Hunault M; Jourdan E; Chermat F; Sebert M; Kroemer G; Fenaux P; Adès L;
Leuk Res; 2014 Dec; 38(12):1430-4. PubMed ID: 25449687
[TBL] [Abstract][Full Text] [Related]
19. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
Alhan C; Westers TM; van der Helm LH; Eeltink C; Huls G; Witte BI; Buchi F; Santini V; Ossenkoppele GJ; van de Loosdrecht AA
Cytometry B Clin Cytom; 2014 May; 86(3):207-15. PubMed ID: 24474614
[TBL] [Abstract][Full Text] [Related]
20. [Myelodysplastic syndrome with rapid disease progression after withdrawal of treatment with azacitidine].
Ueda H; Yoshida M; Kanashima H; Nakao T; Sugiyama H; Yamane T
Gan To Kagaku Ryoho; 2014 Jul; 41(7):875-7. PubMed ID: 25131875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
